Phase I Study of [<sup>68</sup>Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)Odrade Gondry, Marleen Keyaerts, Ilse Vaneycken et al.|Journal of Nuclear Medicine|2023Cited by 45
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Bart Neyns, Yanina Jansen et al.|Cancers|2021Cited by 36
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumabGil Awada, Bart Neyns, İsa Aykut Özdemir et al.|Annals of Oncology|2018Cited by 4
Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.Gil Awada, Bart Neyns, Julia Katharina Schwarze et al.|Journal of Clinical Oncology|2020Cited by 3
68GaNOTA-anti-MMR-Nb for PET/CT assessment of protumorigenic macrophages in patients with solid tumors: preliminary results of a phase I clinical trialOdrade Gondry, Marleen Keyaerts, Catarina Xavier et al.|Unknown|2020Cited by 1